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Background: Prescription information for many drugs entering the market lacks 
dosage guidance for hepatic impairment. Dedicated studies for assessing the fate 
of drugs in hepatic impairment commonly stratify patients using Child- Pugh score. 
Child- Pugh is a prognostic clinical score with limitations in reflecting the liver's meta-
bolic capacity.
Aims: To demonstrate the need for better drug dosing approaches in hepatic impair-
ment, summarise the current status, identify knowledge gaps related to drug kinetic 
parameters in hepatic impairment, propose solutions for predicting the liver disease 
impact on drug exposure and discuss barriers to dosing guidance in those patients.
Methods: Relevant reports on dosage adjustment in hepatic impairment were an-
alysed concerning the prediction of the impairment impact on drug kinetics using 
physiologically- based pharmacokinetic (PBPK) modelling.
Results: PBPK models are suggested as a potential framework to understand drug 
clearance changes in hepatic impairment. Quantifying changes in abundance and ac-
tivity of drug- metabolising enzymes and transporters, understanding the impact of 
shunting, and accounting for interindividual variations in drug absorption could help 
in extending the success of these models in hepatically- impaired populations. These 
variables might not correlate with Child- Pugh score as a whole. Therefore, new meta-
bolic activity markers, imaging techniques and other scoring systems are proposed to 
either support or substitute Child- Pugh score.
Conclusions: Many physiological changes in hepatic impairment determining the 
fate of drugs do not necessarily correlate with Child- Pugh score. Quantifying these 
changes in individual patients is essential in future hepatic impairment studies. 
Further studies assessing Child- Pugh alternatives are recommended to allow better 
prediction of drug exposure.
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1  | INTRODUC TION
Liver metabolism is responsible for the elimination for many drugs. 
The liver has impressive functional hepatic reserve, and conse-
quently, significant hepatic impairment (HI) has to occur before 
changes in drug metabolism occur. Unlike renal impairment (RI), 
there is currently no surrogate markers to estimate HI and limited 
evidence to guide drug dose adjustment.1 HI can be defined as any 
acute or chronic liver injury that affects liver functional capacity. 
Dose adjustment in HI population is challenging as the impact of the 
disease on drugs clearance varies depending on the drug character-
istics as well as individual patient factors.2
Cirrhosis is a significant and increasing burden of disease world-
wide.3 It is the common end- point of most chronic fibrotic liver dis-
eases and the point at which hepatic reserve has been exhausted. 
Consequently, decline in hepatic function is evident with progres-
sive cirrhosis. Multiple interacting factors determine the behaviour 
of drugs in cirrhosis, making drug dose adjustment a challenge. 
Under or over dosing could have significant clinical consequences. 
Therefore, given the prevalence of disease and the importance of 
optimal drug dosing, it is essential to predict drug metabolism. In 
this review, we focus on strategies for drug dosing in liver cirrhosis.
In cirrhosis, the absorption and disposition kinetics of most drugs 
are affected. It changes not only the metabolic function of the liver, 
but it also has an impact on parameters such as liver blood flow, 
binding to plasma proteins and biliary and renal excretion. These 
all potentially influence drug pharmacokinetics (PKs) at different 
degrees depending on the drug and the severity of the disease in 
the patient.4 This in turns may lead to significant alterations in the 
exposure to many drugs, necessitating dosage adjustment to avoid 
drug toxicity.
Dedicated PK studies for HI patients are part of many drug de-
velopment programmes, and there is a regulatory guidance on the 
conduct of such studies and interpretation of the results. This is 
with a view to providing information to prescribers in the drug label. 
However, many drug regulatory authorities may approve drugs prior 
to availability of complete dosage guidance in subgroups of patients, 
such as those with HI.5 This raises the need for evidence- based ap-
proaches to guide clinicians to the best course of action regarding any 
dose adjustment of drugs in HI until clinical evidence is established. 
Physiologically based pharmacokinetic (PBPK) modelling and simula-
tions have been used for this purpose. However optimisation is still 
required to increase the predictive performance of these models. This 
review summarises key requirements for developing PBPK models for 
HI populations, the current scoring systems implemented into these 
models, their limitations and potential to enhance model predictability.
2  | METHODOLOGY
Literature searches were carried out to collate information for vari-
ous sections. In Section 6, the US Food and Drug Administration 
(FDA) labels for new molecular entities (NMEs) approved for the first 
time in the years from 2015 to 2019 were collected from the FDA's 
Center for Drug Evaluation and Research and assessed in relation 
to whether sufficient information on dosing in HI populations was 
included in the labels. This is as a continuation of the previous work 
by Jadhav et al for earlier years (2013- 2014).5
In Sections 7 and 8, a literature search was performed using the 
PubMed repository (https://pubmed.ncbi.nlm.nih.gov/). To collect 
articles reporting PBPK drug models in HI (Section 7), we used the 
search terms: (“PBPK”) and (“Hepatic impairment” or “Cirrhosis”) 
and (“Model”). To collate available data on the abundance and ac-
tivity of drug- metabolising enzymes and transporters (DMET) used 
to populate PBPK models, as described in Section 8.2, the follow-
ing terms were used: (“Abundance,” or an equivalent term: “Level,” 
“Quantification,” “Activity” or “Expression”), (“Cytochrome P450,” 
“Uridine 5′- diphospho- glucuronosyltransferase,” “Metabolising en-
zyme” or “Transporter”) and (“Cirrhosis,” “Liver disease” or “Hepatic 
impairment”). Only original articles published in English during the 
period 1900- 2020 and reporting studies in human subjects were 
included.
3  | CIRRHOSIS EPIDEMIOLOGY, C AUSES 
AND CL A SSIFIC ATION
Cirrhosis is a global health burden, accounting for over 1 million 
deaths per annum, and 4.9%- 9.5% of the global population are be-
lieved to have some level of cirrhosis.6- 8 Alcohol, hepatitis C, hepati-
tis B and nonalcoholic steatohepatitis (NASH) are amongst the most 
common causes of cirrhosis worldwide.9 Different classification sys-
tems have been used for categorisation of cirrhosis, amongst which 
Child- Pugh (CP) classification is the most common.
3.1 | CP system
Liver cirrhosis is routinely classified based on disease progression 
into CP grades, CPA (mild), CPB (moderate) and CPC (severe).10 
Although this classification is widely used clinically and can give 
an indication of the severity of liver disease, it does not express 
quantitative changes in hepatic metabolic function responsible 
for drug clearance.9 Scores in this classification are calculated 
based on encephalopathy, ascites degree (absent, moderate/con-
trolled or severe/refractory), serum bilirubin and albumin levels, 
as well as prothrombin time or the international normalised ratio 
(INR).11
3.2 | Other classification systems
Apart from CP score, several models exist for grading the severity of 
liver disease. The Model for End Stage Liver Disease (MELD) score 
depends on three readily available laboratory variables: serum cre-
atinine, serum bilirubin and INR.12
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The MELD score was developed and validated to predict mor-
tality in patients with portal hypertension undergoing placement of 
transjugular intrahepatic portosystemic shunts, but it is now more 
commonly used to predict survival in cirrhosis and for prioritisation 
of patients for liver transplant.13,14
Another system to assess HI specifically in oncology patients was 
developed by the National Cancer Institute (NCI) Organ Dysfunction 
Working Group (ODWG) to guide dosing for chemotherapeutics.15 
The NCI classification system (NCIc) uses two biochemical param-
eters to grade hepatic dysfunction: total bilirubin and aspartate 
aminotransferase.16
Other classification systems for cirrhosis are available but are not 
frequently used. Most of these correlate with the CP classification, 
including Maddrey's discriminant function (df)17 (using prothrombin 
time and total serum bilirubin) and the Mayo Survival Model for pri-
mary biliary cirrhosis.18
Using specific markers of metabolic activity is an alternative ap-
proach. Monoethylglycinexylidide (MEGX) is a lidocaine metabolite 
(via cytochrome P450 (CYP) 3A) and a biomarker for the assessment 
of oxidative enzymes activity.19 Indocyanine green clearance has 
been validated as a tool for pre- operative assessment of liver func-
tion and also gives indication of hepatic blood flow.20 Consequently, 
it has been assessed as a tool for measuring hepatic function for drug 
metabolism.21 Galactose single point (GSP) is a simple test that can 
be used to define clearance of both highly metabolised drugs and 
drugs which are eliminated without undergoing metabolism in the 
liver.22 GSP was originally reported in 1995, and further validation 
studies are awaited.23 Overall, despite promising results, the lack of 
routine availability limits clinical utility of all these tests.
3.3 | Limitations of the CP scoring system for 
drug dosing
Although the CP score is the most commonly used classification sys-
tem for patients with cirrhosis, it has some limitations that can be 
explained as follows:
1. Subjective scoring: Two elements in CP classification are clinical 
parameters. These are ascites and encephalopathy scores. They 
are subjective according to clinical judgement and can also be 
confused with other disorders.24 For example, a patient with 
liver cirrhosis and diabetes can experience diabetic coma that 
can be mistakenly diagnosed as hepatic encephalopathy. Similarly, 
a patient with a brain tumour along with cirrhosis can show 
symptoms that may be confused with hepatic dysfunction or 
disorder. Metabolic encephalopathy can be also precipitated 
by sepsis or renal insufficiency.25 Ascites severity is also a 
subjective assessment and may be exacerbated by noncirrhotic 
factors, including heart failure, cancer and infectious diseases.26 
Careful clinical diagnosis is required to rule out other causes 
and reduce the subjective nature of these parameters. Other 
scoring systems such as MELD and NCI scores include only 
biochemical laboratory tests to overcome this subjectivity in 
CP scoring.
2. Not accounting for renal function: Although RI is common with 
cirrhosis, this scoring system does not consider changes in renal 
function. For drugs that are mainly eliminated by the kidney, CP 
classification does not help in clinical predictions or correlate with 
drug kinetics. Other scoring systems, such as MELD score, were 
developed to overcome this limitation by including creatinine lev-
els as one of its components.
3. Not distinguishing between the different causes of cirrhotic liver dis-
ease: Several reports have indicated discrepancies between dif-
ferent causes of cirrhosis in relation to enzyme and transporter 
expression, inflammatory mediators, speed of progression and 
control by certain drugs, such as ursodeoxycholic acid (UDCA). 
Scoring systems (ie, MELD) consider cholestatic and alcoholic cir-
rhosis as lower risk than other underlying causes in the formula 
score, but it is uncertain if these aetiologies have better hepatic 
function compared to other disease aetiologies for the same 
biochemistry.27
4. Wide interindividual variability amongst patients assigned the same 
score: As CP scoring stratifies patients into only three categories, 
wide variations in disease prognosis exist amongst patients within 
the same group. A study involving over 1000 patients showed 
that overall survival associated with CPA5 class was significantly 
higher than CPA6.28 This variability becomes more obvious in 
patients with portal hypertension than those without portal 
hypertension.29
5. Correlation with liver metabolic capacity is not well established: CP 
classification was not created to assess liver metabolic function, 
and it utilises assays attributable to synthetic state, function and 
clinical status. However, it is not possible to separate the main 
contributor to CP grade from these three elements. For exam-
ple, a patient with normal metabolic and synthetic liver function 
that has refractory ascites or encephalopathy might be scored 
in the same class as a patient with deteriorated functions and 
normal clinical measures. Those two patients may require com-
pletely different treatment options and drug doses as the meta-
bolic capacity of their livers is widely different. Therefore, the 
use of markers like serum albumin, prothrombin time, and bili-
rubin is encouraged and abnormalities in these parameters may 
be better related to drug elimination capacity than other com-
ponents of the CP classification, for example, encephalopathy 
and ascites as recommended by the European Medicine Agency 
(EMA).30
In spite of all the limitations discussed above, CP scoring sys-
tem is still the most widely used in drug development. This scoring 
system is recommended by the US FDA and the EMA owing to its 
reproducibility, low cost, classification of cirrhosis into only three 
main categories (simplicity of interpretation) and incorporation of 
routinely measured parameters for hepatically impaired patients. 
Ninety five percent of PK studies dedicated for HI populations in 
drug development use CP classification to categorise patients at 
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different stages of disease severities by contrast less than 2% use 
NCI or MELD score exclusively.31
4  | MOVING BE YOND CP SCORING 
SYSTEM
Several attempts have been made to correlate CP score with NCI, 
MELD and other scoring systems15 or to use other noninvasive met-
abolic scoring systems. One or a combination of these methods is 
proposed to overcome the limitations of the CP system. The follow-
ing have been proposed:
Disease severity index (DSI): This test uses metabolism of oral 
and intravenous radioactive cholates that account for the changes 
in first- pass metabolism and the effect of shunting.32 This score 
showed good correlation with CP score but not with the MELD 
score. Although it seems to be a promising noninvasive method, its 
applicability in routine clinical practice and in clinical trials has yet to 
be investigated.
Refining the CP scoring system: The current cut- off points for 
several factors in the CP scoring system (shown in Table S1) were 
not previously validated. Therefore, this scoring system has shown 
some shortcomings in predicting the 5- year survival of patients 
with different aetiologies. A retrospective study was performed 
to refine these cut- off levels for bilirubin, albumin and INR and 
to introduce creatinine levels into the classification system.33 
Although these changes reflected better predictive performance 
for intermediate and long- term survival, they have not yet been 
investigated against the metabolic capacity of the liver for differ-
ent drugs.
Moreover, the objective biochemical components of CP score 
(albumin, bilirubin and prothrombin time) need further validation 
against exposure to a broad range of drugs, in order to confirm util-
ity. In order to progress the field, clinical PK studies should provide 
individual components of a given CP for every patient. Further mod-
ifications may include separation of CPA category into A5 and A6 
subclasses for HI studies, and the presence of portal hypertension 
may provide added benefit. Assessment of these can be done retro-
spectively and on historical studies as long as the records for various 
components making the CP scores were available for re- analysis.
Imaging techniques: Liver stiffness measurements such as tran-
sient elastography correlate with the deposition of hepatic fibrosis 
and can be used to identify patients with cirrhosis and predict pro-
gression to decompensated disease.31 Computed tomography has 
also been used as a tool to scale- up enzyme abundance and activity 
data by measuring the functional hepatocyte volume as a direct re-
flection of the functional reserve of the organ and correlating these 
values with changes in the CP score.34,35 The simulation outputs for 
different drugs were in agreement with the biologically determined 
scalars using microsomal and cytosolic protein contents.36 These 
technologies offer promise, but more studies are required to inves-
tigate the change in the activities of different DMET against image- 
related measures.
5  | REGUL ATORY PERSPEC TIVE ON DRUG 
DE VELOPMENT IN HI
With drug dosing moving from a “one size fits all” approach to more 
“personalised” dosing, individualised tailoring of drug dose to opti-
mise efficacy and minimise harm has become a key focus of inves-
tigation. The US FDA guidance recommends PK studies in patients 
with impaired hepatic function if the hepatic metabolism and/or ex-
cretion accounts for a substantial portion of the elimination of the 
parent drug or its active metabolite(s) (>20% of absorbed dose is 
eliminated by the liver). The guidance also recommends a HI study 
even if the drug and/or its active metabolite are eliminated to a 
lesser extent by the liver when the drug/metabolite has a narrow 
therapeutic index. In the case of drugs that are intended only for 
single- dose administration, a HI study will generally not be neces-
sary unless clinical concerns suggest otherwise.37
These PK studies determine the plasma concentrations of the 
parent drug and sufficiently important active metabolites and calcu-
late PK parameters, such as the area under the concentration- time 
curve (AUC), terminal half- life (t1/2), maximum plasma concentra-
tion (Cmax) and apparent clearance for the parent compound (CL/F). 
For multiple dose studies, trough concentration (Cmin) and fluctua-
tion should be taken into account. When possible, both unbound 
and total concentrations are used to express these parameters. 
Generally, dose reduction is required if the change in the AUC in HI 
exceeds a twofold increase relative to healthy volunteers.37 Usually, 
doses are reduced if the liver disease has resulted in a clinically sig-
nificant impairment in the clearance of the drug except for prodrugs, 
in which doses may be increased or the frequency of administra-
tion may be decreased. In some cases, the drug may be classified as 
contraindicated in severe liver impairment, depending on the drug's 
therapeutic window and the impact on the clearance of the drug. 
In the case of lack of data supporting drug labelling, the drug may 
be classified as “used with extreme caution”.38 To ensure equitable 
access to patients with cirrhosis to potentially safe and efficacious 
medication, it is critical that drugs are appropriately scrutinised in HI.
6  | THE NEED FOR DOSE ADJUSTMENT  
IN HI
Around 50%- 80% of NMEs approved in the United States between 
the years 2013 and 2014 did not include clinical studies that inform 
dosage recommendations in RI and HI, irrespective of whether these 
clinical trials were required.5 The percentage of drugs which did not 
have dosing recommendations for mild and moderate HI at initial ap-
proval was ~30% and 50%, respectively, in both of the years 2013 
and 2014. However, for severe HI, this proportion was close to 80% 
in 2013 and ~60% in 2014, as shown by the left part of Figure 1 de-
rived from data published by Jadhav et al.5
We followed the same strategy and found that a similar trend 
persisted in subsequent years in the period 2015- 2019 (Table S2). 
Biologics were not included in this survey. In 2015, about 36%, 33% 
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and 72% of the NMEs lacked study- based label guidance for mild 
(CPA), moderate (CPB) and severe (CPC) cirrhosis, respectively. In 
the following 4 years (2016- 2019), the situation remained similar 
with a gradual rise in the percentage of drugs without label guidance, 
mainly in the severe stage of cirrhosis, as shown in Figure 1. These 
drugs are now available in the market without any labelling guidance 
regarding their dose levels in this special patient population.
During the different phases of clinical trials, patients are recruited 
and treated by the investigational drug to test its safety and efficacy. 
Many special patient populations are excluded during these phases 
to avoid subjecting those individuals to any risks of unexpected side 
effects due to inappropriate dosing. However, extensive narrowing of 
the inclusion criteria or expansion of the exclusion criteria without an 
obvious aim may influence the inference and usefulness of clinical trials 
with respect to different issues. First, a large number of patients may 
miss the opportunity to participate in such trials that may be clinically 
beneficial. Second, trial results will be less likely to capture the diver-
sity in patient populations that might be exposed to this therapy after 
being released onto the market. The study population may in fact only 
represent a small fraction of the market population. Third, extensive 
time wastage in the recruitment of patients can occur with “restricted” 
criteria in all phases of clinical studies.39
Ironically, when we examine the exclusion criteria related to organ 
dysfunction, one can find that these exclusions are based on liver 
function tests (LFTs) and CP scores, in the case of hepatic dysfunction. 
Unlike renal dysfunction, where creatinine clearance can be a reliable 
measure of renal clearance, neither LFTs nor CP score accurately re-
flects the drug- metabolising efficiency of the liver. The upper limits 
of normal (ULN) range for LFTs, such as aspartate transaminase (AST) 
and alanine transaminase (ALT), is around 40 IU/L.40 These can vary 
between populations according to sex, age and weight of the patient 
as well as between laboratories.41 Some patients with mild and mod-
erate HI may have LFTs between 5 and 20 folds the ULN; however, 
they can still tolerate the approved doses without any symptoms or 
complications. Thus, for drugs metabolised by the liver, a total exclu-
sion of patients with liver enzymes above twofold to threefold ULN 
does not necessarily correlate to liver dysfunction and the lack of more 
metabolic- reflective measures is an urgent issue.42
Due to the aforementioned reasons, the American Society of 
Clinical Oncology (ASCO) adopted a suggestion to modify the eligi-
bility criteria in cancer research clinical trials to be more inclusive of 
patients with organ dysfunction as long as the dose is suitably ad-
justed based on evidence- based data.43 After this recommendation, 
the FDA published a guidance document for broadening eligibility 
criteria to increase diversity in enrolment and to include more pa-
tients from underrepresented populations.44
7  | C AN PBPK MODELLING HELP IN 
FILLING THE GAP IN DEDIC ATED CLINIC AL 
TRIAL S?
Although PBPK modelling may inform regulatory approval for many 
drugs and in different situations with more confidence in relation 
to drug- drug interactions and paediatric applications, only a small 
number of FDA submissions use PBPK for predicting drug exposure 
in HI. Different physiological changes in cirrhosis with disease pro-
gression were reported to have an impact on drug exposure, such 
as changes in blood flow to the gut, liver, kidneys and other organs, 
plasma protein levels, haematocrit level, liver size, DMET expression 
and activity both in the liver and the gut, renal function and liver 
circulation, including shunting.34,35
As described in Section 2, articles that assessed PBPK models 
for different drugs in HI populations were collected irrespective 
of the software tool used for model development. This search re-
sulted in 60 different publications that match the search criteria, of 
which only 14 were relevant to the purpose of this review (Table S3). 
Application of the above mentioned changes in the models produced 
good predictions (predicted outcomes within twofold of observed 
data).35 However, poor predictive performance of these models has 
been reported in other scenarios, which have shown underpredic-
tion of clearance of the modelled drugs, especially in moderate and 
severe stages of cirrhosis (Figure 2 and Table S3). No single factor 
can be the source of these biases, as they are not related to com-
mon features of the drugs. For example, some models for CYP2D6 
substrates showed good performance with moderate HI populations 
as in the case of eliglustat,45 whilst others such as atomoxetine did 
not.46 However, some of these studies used different software tools 
and different model structures. The IQ consortium has recently 
conducted a comprehensive PBPK modelling and simulation re-
search with fixed physiological parameters on nearly 60 drugs and 
concluded that about 70% of the predicted performance was within 
twofold.47 Similar to previous studies, most of the 30% outliers were 
observed in moderate and severe HI populations. Improved under-
standing of these pathophysiological processes in advanced disease 
and an appropriate classification system of HI are needed. Stratifying 
F I G U R E  1   The percentage of new molecular entities (NMEs) 
approved without explicit dosing recommendations in hepatic 
impairment population on their initial approval from 2013 to 2019 
(data for the first 2 years are derived from Jadhav et al,5 whilst the 
rest represents data from the current review for the period from 
2015 to 2019)
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patients based on liver metabolic capacity and availability of clinical 
data for model's validation would improve predictive performance, 
reliability and utility of these models.
The use of PBPK modelling in drug development has grown over the 
years to inform dosing, optimise clinical study design, shorten the dura-
tion of clinical studies and simulate untested scenarios (such as steady 
state exposure, drug- drug interactions or different doses and/or for-
mulations).48 This approach is thought to be valid for noncirrhotic liver 
diseases, such as earlier hepatic steatosis or fatty liver disease,49 as long 
as the degree of change in physiological (system) parameters related to 
drug PKs (as mentioned above) is well known. For oncology drug expo-
sure in patients with hepatocellular carcinoma, other classification sys-
tems such as the albumin- bilirubin (ALBI) grade were recommended.50,51
8  | CURRENT GAPS AND CHALLENGES 
FOR PBPK MODELLING IN HI 
POPUL ATIONS
8.1 | The heterogeneous nature of the disease and 
the scoring system
As pointed out earlier, chronic liver disease is progressive and dif-
ferent grades and classifications are available with different scoring 
systems. The mild grade of CP classification is variable with widely 
different survival rates depending on whether the disease is asso-
ciated with portal hypertension or not.52 Other scoring systems do 
not correlate well with CP score making the use of these systems 
interchangeably very difficult. Moreover, the level of change in the 
expression and activity of different DMET is not the same across 
scores and is also affected by the aetiology of the disease and its sur-
rounding environment.36,53 This can be partly attributed to the fact 
that the liver is actually not “well- stirred” as usually assumed in differ-
ent models. The well- stirred model assumes that the liver is a single 
well- stirred compartment and that the unbound drug concentration 
in the emergent blood is in equilibrium with the unbound drug within 
the liver.54 Some preclinical evidence has shown that interzonal and 
interlobar differences in the distribution of enzymes and transporters 
as well as the location and degree of liver disease can have a key role 
in predicting the PK outcome.55- 57 Therefore, designing a dedicated 
study using the most common scoring system, such as CP scoring, 
with all its limitations with regard to assessment of hepatic metabolic 
capacity, makes dosage adjustment for those patients and extrapola-
tion of PBPK models for liver disease more challenging.
8.2 | Information on abundance and 
activity of DMET
8.2.1 | Drug- metabolising enzymes
Xenobiotic detoxification process in the liver relies on the presence of 
metabolic enzymes. Within the hepatocyte, transforming enzymes are 
primarily located in the microsomes (small vesicles) of the endoplasmic 
reticulum and the soluble fraction of the cytoplasm (cytosol). The im-
pact of impairment on drug clearance varies depending on the meta-
bolic reaction involved to clear this drug and the functional reserve of 
these enzymes in the liver. Phase I metabolism is usually known to be 
significantly affected by the severity of hepatic dysfunction to a higher 
degree than phase II conjugation reactions. The difference between 
phase I and phase II biotransformation in response to HI supports the 
oxygen limitation theory.58 This theory is based on the assumption of 
reduced oxygen transfer from blood to hepatocytes by capillarisation 
of sinusoids and cirrhotic tissue development. It relies on the observa-
tion that oxidative Phase I reactions are substantially reduced in liver 
disease, whilst Phase II (conjugative) metabolic reactions are preserved 
until end- stage liver disease is reached.59 For example, theophylline 
clearance, which depends mainly on CYP450 oxidative metabolism, 
was shown to be reduced by 37% in cirrhotic rats and activity was 
restored to normal values by oxygen supplementation.60
Some clinical studies showed that glucuronidation does not 
appear to be altered except when hepatic cell mass is reduced 
abruptly,61,62 whilst others found that some patients with severe he-
patic disease exhibited an increase in enzyme activities.62,63 Debinski 
et al64 demonstrated upregulation of UDP- glucuronosyltransferase 
(UGT) enzymes in the remaining viable human hepatocytes of dis-
eased livers, as observed using immunohistochemical staining 
(Table S5). Impaired glucuronidation is observed for drugs, such as 
morphine, lamotrigine, lometazepam, zidovudine and mycopheno-
late mofetil, especially in advanced stages of cirrhosis.62
Clinical studies have also shown that the biotransformation 
of CYP3A4 substrates, such as midazolam or erythromycin, is 
F I G U R E  2   The predictive performance of published models for 
20 different drugs in hepatic impairment populations with different 
severities (mild, moderate and severe cirrhosis). Data were obtained 
from 14 studies35,45,46,76,86,98- 106
     |  7EL- KHATEEB ET AL.
significantly reduced in severe HI, whilst for CYP2C, the situation 
is different as the expression trends of these enzymes are highly 
variable (ranging from no change in liver disease to about 34%- 72% 
of that in healthy control subjects). Murray et al recently concluded 
that CYP2C protein expression is not impaired in cirrhotic livers by 
studying selective drug substrates.65
Studies using immunochemical quantification reported variabil-
ity in the microsomal levels of different CYP isoforms with differ-
ent sensitivities toward disease progression as shown in Figure 3 
and Table S4.66- 68 This wide variation in the response of enzymes 
to hepatic injury is most probably linked to the disease stage and 
its severity as proposed by Frye et al who suggested a “sequential 
progressive model of hepatic dysfunction,” leading finally to a de-
crease in the activity of most CYP450 enzymes in end- stage liver 
disease.69 Moreover, a doubling in CYP2E1 activity and depletion in 
glutathione levels were revealed in chronic alcohol ingestion, lead-
ing to lower protection against paracetamol, isoniazid, methotrexate 
and other substrates of this enzyme.62
There are several methods for assessing metabolic enzyme ac-
tivity and expression in cirrhotic patients and comparing them to 
healthy control subjects. One of these methods is the measure-
ment of tissue- specific mRNA expression either through reverse 
transcription (RT)- quantitative polymerase chain reaction (PCR) or 
microarrays.70,71 In spite of the utility of this approach, many limita-
tions have been reported, including the following:
• Providing a relative quantification between tissues.
• mRNA does not always correlate with protein abundances such as 
the weak correlation for most CYP450s57 and UGTs.72
• Dependence on mRNA synthesis and degradation rather than 
protein turnover.
Another commonly used approach is the use of selective probe 
drugs for a limited number of enzymes (Table 1). These probes should 
have a high degree of enzyme selectivity either in vitro or in vivo.69,73,74 
However, this technique has the limitation of small sample size (limited 
number of patients) in addition to the interference of other factors 
that may affect the study results, such as other elimination pathways 
(eg, renal elimination), inaccuracy in metabolic ratio calculations for 
complex pathways75 and the effect of genotype differences.76
Apart from relative quantification, absolute quantification of 
protein abundances is relatively recent with limited studies available 
(Tables S3 and S4). It provides the possibility of measuring absolute 
and direct protein amounts for incorporation into PBPK models and 
bridging between studies without the necessity of correlation to a 
reference sample. Different techniques have been used for protein 
quantification, such as immunoblotting as well as label- free and 
isotope- labelling proteomic techniques. The choice of suitable meth-
odology depends on the sample under study, the number and nature 
of the target proteins being quantified, whether discrimination of 
isoforms of the same subfamily is required and the overall cost.70,77
According to Prasad et al,76 the changes in abundance of CYPs, 
UGTs and other drug- metabolising enzymes in cirrhotic livers are 
dependent not only on the enzyme but also on the origin or cause 
of cirrhosis. For example, there is an evidence of more extensive re-
duction in drug- metabolising enzyme abundance in alcoholic cirrhosis 
than hepatitis C- induced cirrhosis.76 However, this study did not as-
sess changes in enzyme abundances for mild and moderate cirrhosis 
F I G U R E  3   Changes in the abundances (A) and activities (B) of different CYP450 isoforms in cirrhotic liver disease relative to control, as 
reported in the literature.57,67,68,69,73,74,76 Activities are assessed in vivo using selective probes at different stages of disease progression. 
Abundances were measured my immunoblotting, immunohistochemistry or proteomics per milligramme liver microsomes obtained from 
either control or cirrhosis livers. HC, hepatocellular liver disease; CHOL, cholestatic liver disease; CPA, Child– Pugh score A; CPB, Child– Pugh 
score B; CPC, Child– Pugh score C
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patients or zonal differences in these abundances across the liver. 
Moreover, some of the enzymes, such as CYP2B6, CYP3A5, UGT2B17 
and UGT1A1, were below the detection limit of the analytical method.
8.2.2 | Transporters
Drug transporters are membrane- bound proteins present in organs, 
such as the intestine, liver and kidneys, and they play a key role in the 
absorption and elimination of drugs and their metabolites. Figure 4 
shows the most important transporters in drug disposition within 
the liver. Drug transporters are categorised either functionally into 
two superfamilies: uptake transporters or phase 0 proteins and ef-
flux transporters or phase III proteins or structurally mainly into sol-
ute carriers (SLC) and ATP- binding cassette (ABC) transporters.78,79
Relative transporter mRNA levels have previously been mea-
sured by quantitative PCR at different stages of HCV liver disease.71 
NTCP and OCT1 showed a significant rise in mild F1 fibrosis relative 
to normal control (~75% and 38%, respectively), whilst later stages 
showed a nonsignificant difference in NTCP expression relative to 
healthy subjects and a significant reduction, by 38%, in OCT1 levels 
in severe cirrhosis. On the other hand, OATP- C transporters showed 
a gradual reduction of 16%, 20% and 60% with F1, F2, to F3 fibrosis 
scores, respectively.
TA B L E  1   Activity studies for different CYP450 isoforms at different degrees of disease severity with the applied indices and probes
Study
Stage of liver 
disease CYP isoform Probe
Cause of cirrhosis 








All are alcoholic (26) • Plasma concentration of MEGX metabolite in the 
15- min postinjection
• Urine recovery of the hydroxyl metabolite after 
2, 4 and 24 h from the oral dose











HCV (14), HBV 
(1), chemical (1), 
alcoholic (2), PSC (1), 
cryptogenic (1)
• Cp of Paraxanthine
Cp of caffeine
in the8 − hpostdosesample
• Urinary recovery of hydroxyl metabolite/(urine 
recovery of parent (mephenytoin)+metabolite)
• Urinary recovery of hydroxyl metabolite/(urine 
recovery of parent (debrisoquin)+metabolite)
• Cp of hydroxymetabolite
Cp of the parent (Chlorzoxazone)
in the4−hpostdosesample






Not specified Urine was collected over 192 h
• Urinary recovery of 4- hydroxymephenytoin
• Urinary excretion ratio of the 
hydroxydebrisoquin relative to 
(debrisoquin+hydroxydebrisoquin urine 
recoveries)
Abbreviations: Cp, plasma concentration; HBV, hepatitis B virus infections; HBV, hepatitis C virus infections; iv, intravenous dosing; P.O, Per oral 
dosing, MEGX, monoethylglycinexylidide (lignocaine metabolite).
F I G U R E  4   Location of clinically relevant drug transporters expressed in human hepatocytes. Uptake transporters located in the 
basolateral membrane include members of the SLC superfamily, such as OCT1, OCT3, OAT2, OAT7, OATP1B1, OATP1B3, OATP2B1 and 
NTCP. Efflux transporters located in the basolateral membrane include members of the ABC transporters superfamily, such as MRP3, MRP4 
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Ogasawara et al also investigated the effect of HCV- related cir-
rhosis on 17 different hepatic drug transporters and observed that 
the expression of most of these transporters (OCT1, OATP1B1, 
OATP1B3, MATE1, MRP4, MRP5 and BCRP) decreased by approxi-
mately 50% in cirrhosis.80 This does not only affect the hepatic up-
take of drugs via these transporters but also biliary excretion was 
also noticeably reduced.
More and co- workers studied transporter mRNA (using 
QuantiGene Plex 2.0 assay) as well as relative transporters protein 
expression (using Western blotting) in human liver tissues with ste-
atosis (with no cirrhosis), alcoholic cirrhosis or diabetic alcoholic cir-
rhosis compared to normal livers.81 A summary of the results of the 
study is shown in Table 2. This study did not assess the activity at dif-
ferent stages of disease severity and did not measure OATP1B1/1B3 
because of lack of commercially available high- quality specific an-
tibodies for these transporters at the time of the study. Moreover, 
the results are not scalable to liver tissue levels, which limit their 
usefulness in modelling. Recent studies assessed changes in trans-
porter abundances per unit mass of tissue using LC- MS proteomic 
techniques in samples with different causes of cirrhosis82,83 and re-
ported progressive reduction of most key transporters with disease 
progression.83
In spite of the impact of cirrhosis aetiology on enzyme expres-
sions, hepatocyte uptake and biliary excretion, the current CP clas-
sification does not differentiate between the different causes of the 
disease as previously indicated.
8.3 | Small sample size in dedicated clinical studies
In clinical studies dedicated to HI, which are designed to develop-
ing dosage recommendations, subjects are stratified based on CP 
score with at least six subjects per arm.37 Although the guidance 
states that for pathways known to exhibit genetic polymorphism 
(such as CYP2D6 and CYP2C19) the number increases and should 
include no less than eight subjects per arm, this still might not 
be enough to represent the whole population and allow accurate 
prediction of drug exposure changes in HI. Other causes of differ-
ences can be age, weight, smoking, concomitantly administered 
drugs and other disease states that are not completely reported 
for every patient. Moreover, most of these dedicated studies do 
not enrol all classes of liver impairment (Figure 1). In some situ-
ations, reduced (in terms of the acceptable number of enrolled 
patients) clinical trials are accepted when the oral clearance of 
TA B L E  2   Transporter mRNA and protein expression in cirrhotic livers with different aetiologies
Cause of cirrhosis
No change from control 
(↔) Decreased compared to control (↓ %) Increased compared to control (↑ %)
Transporter mRNA expression
Alcohola  SLCO1B1, ABCC2, ABCC3, 
ABCC6
SLCO1B3 (78%) SLCO2B1 (51%), ABCC1 (38.44%), 
ABCC4 (58%), ABCC5 (34%), ABCG2 
(194%)








Alcohol and diabetes 
mellitusa 
ABCC2 ABCC6 (~30%- 40%) ABCC1 (1.5- 2 folds)




Alcoholb  SLC47A1, ABCC2, ABCB1, 
SLCO2B1
SLC10A1 (35%), SLCO1B1 (55%), 
SLCO1B3 (87%), SLC22A1 (73%), 
ABCG2 (50%), ABCB11 (36%)
ABCC3 (38%)
Alcoholc  — SLC10A1 (24%), SLCO1B1 (39%), 
SLCO1B3 (21%), SLC22A7 (74%), 
ABCC2 (70%), and OATP2B1 (27%)
— 
Chronic hepatitis Cb  ABCG2, ABCC3, SLCO1B1 ABCB11, ABCC2, SLCO10A1, SLCO1B3, 
SLC22A1, ABCB1 (32%- 56%)
SLC47A1 (46%)
Chronic hepatitis Cc  — ABCB11 (53%), SLCO2B1 (26%) — 
Cholestatic liver diseasec  — — ABCB1 (~3.5 folds), ABCC4 (~3 folds)
Autoimmune hepatitisc  — ABCC2 (82%) ABCB1 (~4folds), ABCC4 (~2.5 folds)
aData derived from Ref.81
bData derived from Ref.82
cData derived from Ref.83
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the drug shows a negative correlation with the progression of the 
disease. In that case, the findings in the moderate category would 
be applied to patients with a mild CP category, and dosing in the 
severe category would generally be contraindicated.37 However, 
dosage adjustment in moderate HI cannot be generalised or ex-
trapolated to mild or less severe conditions and the drug can be 
still useful in severe stages with appropriate dosage adjustment.
8.4 | Accounting for the change in plasma protein 
binding in HI patients
Plasma protein concentrations mainly albumin and α1 acid glycopro-
tein are known to decline with progress of HI severity.84 The fraction 
unbound of a drug is the proportion that is responsible for thera-
peutic effect and available for systemic metabolism and elimination 
which can be calculated in HI from Equation 1. Scaling with this 
equation was shown to have high predictive performance especially 
for albumin bound drugs.84
where fu,normal and fu,HI denote free drug fraction in plasma in normal 
and HI subjects, respectively. [P]normal and [P]HI the plasma protein con-
centrations in normal and hepatic disease, respectively. Although the 
prediction of the absolute value of fu was good, the authors did not 
assess the predictive performance based on the relative changes of fu 
(by comparing the observed and predicted changes of different drugs 
in various HI populations).
When doses are intended to be adjusted in cirrhotic patients, 
CL/Funbound and AUCunbound are the parameters that should be taken into 
account rather than the total parameters; CL/Ftotal and AUCtotal (bound 
and unbound) as the latter are deceiving. For instance, the AUCtotal 
may not change or, on the contrary, may decrease, whilst the unbound 
value, which is more clinically relevant, increases. This conclusion has 
been recommended by many studies and was observed for different 
drugs, such as naproxen,85 carvedilol86 and quinine.87 The decrease in 
CL/Funbound is obscured by the increase in the unbound fraction of the 
drug in the blood fub as can be deduced from the following equation:
Therefore, the net result may be unchanged total CL/Ftotal as in 
the case of naproxen in cirrhotic patients compared to that in healthy 
controls or a worse result as in the case of quinine, which showed an 
increase in CL/Ftotal for cirrhotic patients relative to healthy individ-
uals. This may lead to a major error in dose adjustment. This factor 
will mainly affect the systemic clearance of low clearance or low ex-
traction ratio drugs.88
It is also important to note that differences in protein binding 
obtained from in vitro experiments and in vivo situations can be 
observed,89,90 and this can contribute to the poor predictive perfor-
mance for some drugs in HI populations.
8.5 | The shunting effect
Due to the progressively developing portal hypertension with in-
creasing cirrhosis severity, spontaneous porto- systemic shunts (SPSS) 
are formed to vent the increased portal pressure.91 Unfortunately, 
although this mechanism seems to be compensating for deteriora-
tion during cirrhosis, complications such as hepatic encephalopathy, 
variceal bleeding, portal vein thrombosis and deterioration of liver 
function start to appear.92 Concerning PKs of administered drugs, 
these SPSS as well as surgically implemented TIPS constitute a chal-
lenge to the predictive performance of different models. TIPS can 
lead to a reduction in gut CYP3A4 levels as well as levels of hepatic 
enzymes.93 Therefore, changes in the mesenteric blood flow and 
CYP3A4 should be accounted for in the models based on the presence 
or absence of these shunts, their severities and the stage of cirrho-
sis.35,94 Computed tomography images can help in visualisation and 
identification of SPSS. It should be highlighted that the MELD score 
fails to capture severity of portal hypertension, whilst CP does reflect 
this to an extent, but neither of these scoring systems addresses the 
presence or severity of spontaneous portosystemic shunting.
8.6 | Impact of HI on drug absorption is not 
well understood
As pointed out earlier, the degree of shunting and the corresponding 
changes in mesenteric blood flow and intestinal enzyme abundances 
and activities in HI can affect oral drug bioavailability.62,93 The bio-
availability of drugs such as morphine, meperidine, verapamil, me-
toprolol, clomethiazole, labetalol, carvedilol and midazolam may 
increase to double their values in cirrhosis because they escape ex-
tensive first- pass metabolism.
One of the changes that may occur in severe HI is the change in 
the gastric emptying time. In a PBPK modelling and simulation study 
that compared the residence times of metformin in the elderly and 
young populations with and without HI, a 40%- 50% increase in gas-
tric emptying time was suggested in patients with CP- C compared to 
their healthy control counterparts.95 Although these findings have 
not been validated by clinical data, this change may not only cause 
a slight delay in Tmax (time to Cmax) or the rate of absorption but may 
also play a role, to some degree, in alteration of the extent of absorp-
tion in these populations.
9  | FUTURE DIREC TIONS
Given the limitations in the classification systems of HI, it is clear 
that there is no magic number that can be applied to all drugs 
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of disease severity and interindividual variation cannot reliably 
predict differences in exposure to therapeutic drugs. Genotyping 
is one of the key methods that have previously been used to in-
dividualise patient's therapy; however, there are still variabili-
ties amongst patients with the same genotype. Liver biopsy is 
an invasive and impractical approach to the characterization 
of individual patients by direct measurement of the expression 
of metabolising enzymes and transporters or their activities. 
Therefore, newly developed liquid biopsy and multi- omic tech-
niques are proposed as a minimally invasive alternative to tissue 
biopsies by measuring plasma biomarkers that reflect the liver's 
metabolic capacity.96 The link between liquid biopsy and tissue 
is predicated on accounting for the continuous shedding into the 
bloodstream of exosomes that contain a sample from the intracel-
lular bimolecular pool of liver tissue. This technology has recently 
been applied to the characterisation of various hepatic enzymes 
and transporters at baseline and after drug treatment in healthy 
controls and liver cancer patients.96,97 The technique has the po-
tential of monitoring not only markers of hepatic elimination of 
drugs but also biomarkers of disease severity and progression. 
However, the use of this technique for the highlighted application 
requires further assessment in liver disease to demonstrate its 
applicability in clinical practice.
10  | CONCLUSION
There is an unmet clinical need for dose adjustment in HI, especially 
for drugs that have been released to the market and are lacking ap-
propriate guidance in patients with liver disease. PBPK modelling 
and simulations tool was proposed to address this gap. Dedicated 
PK clinical studies required for dosage adjustment in HI and for the 
validation of PBPK models use CP system for patients' stratification 
which has significant limitations. Other scoring systems, DSI, and 
imaging techniques and the emerging liquid biopsy technology, can 
be introduced to overcome some of CP pitfalls. It is unlikely that CP 
score will be replaced in the near future by an alternative stratifica-
tion system for dose adjustment in HI. Nonetheless, efforts to im-
prove stratification of hepatic drug clearance should be encouraged, 
especially given the poor performance of current methodology to 
capture exposure changes for some drugs.
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